CA3186896A1 - Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 - Google Patents
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4Info
- Publication number
- CA3186896A1 CA3186896A1 CA3186896A CA3186896A CA3186896A1 CA 3186896 A1 CA3186896 A1 CA 3186896A1 CA 3186896 A CA3186896 A CA 3186896A CA 3186896 A CA3186896 A CA 3186896A CA 3186896 A1 CA3186896 A1 CA 3186896A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- prodrug
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055970P | 2020-07-24 | 2020-07-24 | |
| US63/055,970 | 2020-07-24 | ||
| PCT/US2021/042874 WO2022020661A1 (en) | 2020-07-24 | 2021-07-23 | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3186896A1 true CA3186896A1 (en) | 2022-01-27 |
Family
ID=77338897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3186896A Pending CA3186896A1 (en) | 2020-07-24 | 2021-07-23 | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295146A1 (https=) |
| EP (1) | EP4185568A1 (https=) |
| JP (1) | JP7769404B2 (https=) |
| CN (1) | CN116057051B (https=) |
| AU (1) | AU2021311811A1 (https=) |
| CA (1) | CA3186896A1 (https=) |
| WO (1) | WO2022020661A1 (https=) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR900482A (fr) | 1942-12-17 | 1945-06-29 | Fides Gmbh | Condensateur électrostatique avec diélectrique consistant au moins partiellement en produits de transformation non conducteurs d'une armature |
| FR66979E (fr) | 1953-06-22 | 1957-11-04 | Glaenzer Spicer Sa | Support pour arbre rotatif |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| US8987275B2 (en) * | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| RU2730016C2 (ru) * | 2015-02-05 | 2020-08-14 | Мерк Патент Гмбх | Макроциклические соединения в качестве irak1/4 ингибиторов и их применение |
| AU2017363313B2 (en) * | 2016-11-22 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| EP3642201A1 (en) * | 2017-06-21 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Isoindolinone derivatives as irak4 modulators |
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
-
2021
- 2021-07-03 US US18/017,759 patent/US20230295146A1/en active Pending
- 2021-07-23 WO PCT/US2021/042874 patent/WO2022020661A1/en not_active Ceased
- 2021-07-23 CN CN202180054152.8A patent/CN116057051B/zh active Active
- 2021-07-23 EP EP21755252.0A patent/EP4185568A1/en active Pending
- 2021-07-23 CA CA3186896A patent/CA3186896A1/en active Pending
- 2021-07-23 JP JP2023504544A patent/JP7769404B2/ja active Active
- 2021-07-23 AU AU2021311811A patent/AU2021311811A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185568A1 (en) | 2023-05-31 |
| WO2022020661A1 (en) | 2022-01-27 |
| JP7769404B2 (ja) | 2025-11-13 |
| AU2021311811A1 (en) | 2023-03-02 |
| JP2023535725A (ja) | 2023-08-21 |
| US20230295146A1 (en) | 2023-09-21 |
| CN116057051A (zh) | 2023-05-02 |
| CN116057051B (zh) | 2025-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023203860B2 (en) | Modulators of the integrated stress pathway | |
| JP7817941B2 (ja) | Ｍｄｍ２分解剤およびそれらの使用 | |
| AU2020234712B2 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| AU2020266592B2 (en) | Substituted cyclolakyls as modulators of the integrated stress pathway | |
| AU2018358160B2 (en) | Modulators of the integrated stress pathway | |
| ES2870920T3 (es) | Inhibidores de CXCR4 y usos de los mismos | |
| AU2019290197B2 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| CA3161878A1 (en) | Irak degraders and uses thereof | |
| AU2012222149B2 (en) | Cannabinoid receptor modulators | |
| JP6404332B2 (ja) | 新規な、ＮＩＫ阻害剤としての３−（１Ｈ−ピラゾール−４−イル）−１Ｈ−ピロロ［２，３−ｃ］ピリジン誘導体 | |
| CA3027495A1 (en) | Cxcr4 inhibitors and uses thereof | |
| MX2014004859A (es) | Nuevos compuestos. | |
| MX2014004857A (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| JP2017531677A (ja) | 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体 | |
| CA2982270C (en) | Novel 7-dehydrocholesterol derivatives and methods using same | |
| WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists | |
| CA3186896A1 (en) | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 | |
| WO2020260857A1 (en) | Hydroxamate compounds as antagonists of the adenosine a2a receptor | |
| WO2022155593A1 (en) | Inhibitors and degraders of janus kinase 2 | |
| US20240299299A1 (en) | Compositions and methods for increasing the efficacy of immunotherapies and vaccines | |
| WO2021216670A1 (en) | Inhibitors of human epididymus protein 4 | |
| WO2025217094A1 (en) | Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof | |
| WO2025217096A1 (en) | Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof | |
| RU2787428C1 (ru) | Ингибитор cd73, метод его получения и его применение | |
| CA3020275C (en) | Mdm2 protein degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240724 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250716 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250718 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250923 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250923 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250923 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250923 |